Respiratory Diagnostics Market: Growth, Size, Share, and Trends
Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer ) and Diagnosis Type (Syndromic, Aetiological, Prognosis) - Global Forecast to 2030
USD 9.02 BN
MARKET SIZE, 2030
CAGR 6.5%
(2024-2030)
404
REPORT PAGES
489
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global respiratory diagnostics market is projected to reach USD 9.02 billion by 2030 from USD 6.17 billion in 2024, at a CAGR of 6.5% from 2024 to 2030. The major factors driving the growth of this market include the rising incidence of respiratory disorders, the expanding geriatric population, growing awareness about respiratory health, and advancements in diagnostic technologies
KEY TAKEAWAYS
-
BY PRODUCT & SERVICEBy product & service, the market is segmented into instruments & devices, assays & reagents, and services & software. The assays & reagents segment is expected to grow at the highest CAGR during the forecast period. This high growth rate of this segment is attributed to the increasing demand for advanced & highly effective assay reagents, improvements in manufacturing capabilities for consumables, and the growing volume of diagnostic samples. Assays & reagents are single-use consumables with a relatively shorter shelf life, hence, steady replenishments contribute to further growth of this segment.
-
BY TEST TYPEThe mechanical tests segment accounted for the largest share of the market as there has been an increase in respiratory health awareness along with advancements in various diagnostic methods. The mechanical test segments are further bifurcated into pulmonary function tests, obstructive sleep apnea diagnostics tests, and other mechanical tests. The pulmonary function tests segment is sub-segmented into three categories: spirometry, peak flow tests, and other pulmonary function tests. Respiratory conditions are being addressed widely, and there is an increasing demand for accurate and reliable diagnostic tests. Increased awareness about health and technological improvement is favoring the market growth for the mechanical test segment in 2024
-
BY DISEASE TYPEBy disease type, the respiratory diagnostics market includes COPD, asthma, tuberculosis, lung cancer, and other diseases. The COPD segment is estimated to grow at the highest CAGR, owing to the increasing prevalence of COPD in young adults & elders, the rising consumption of tobacco products, and the increasing frequency of being exposed to environmental pollutants. Moreover, worsening air quality in emerging markets is expected to further propel the demand for respiratory diagnostics for COPD patients during the forecast period.
-
BY DIAGNOSIS TYPEBased on diagnosis type, the market is clasified into syndromic, etiological, and prognosis dignosis. The syndromic segment accounted for the largest market share in 2023. This methodology detects complex genetic disorders that overlap in phenotypical appearances. Some factors associated with the growth trend include the growing need for early and accurate diagnosis, advancements in diagnostic technologies, and increasing healthcare investments.
-
BY END USERBy end user, the hospitals segment dominated the respiratory diagnostics market. The key factors contributing to the market growth of this segment can be attributed to factors such as the high purchasing rate of hospitals to buy innovative equipment for respiratory diagnostics and the increasing footfall of patients in this end-user segment. The high healthcare expenditure of hospitals; rising technological advancements in diagnostics technologies; and the uptake of technologically advanced solutions across hospitals are also expected to fuel market growth of this segment.
-
COMPETITIVE LANDSCAPEMajor market players have adopted both organic and inorganic strategies, including partnerships and investments. For instance, Koninklijke Philips N.V. (Netherlands), BD (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), and GE Healthcare (US) have entered into a number of agreements and partnerships to cater to the growing demand for adoption of advanced resiratory diagnostics products
The key factors driving market growth include the increasing prevalence of respiratory disorders; expanding geriatric population and rise in sedentary lifestyles; growing awareness about respiratory health; and advancements in diagnostic technologies. However, the high cost of diagnostic tests and limited reimbursements for respiratory surgical procedures are expected to restrain the market growth to a certain extent.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The respiratory diagnostics market's evolving landscape highlights the shift from traditional revenue sources to emerging opportunities. The market primarily relies on devices like spirometers, peak flow meters, pulmonary function testers, and mechanical diagnostic tests. However, the emergence of new technologies and changing healthcare dynamics is reshaping the market. Advanced point-of-care diagnostics, molecular diagnostics, telemedicine, remote diagnostics, and advanced imaging technologies represent significant growth areas. These innovations offer faster, more accurate, and accessible diagnostic solutions catering to various end-users, including hospitals, clinics, diagnostics laboratories, long-term care facilities, specialty centers, and research institutions. Moreover, this transformation is driven by a growing emphasis on early disease detection, personalized medicine, and remote healthcare. As a result, the market is witnessing a shift towards newer revenue sources, presenting exciting opportunities for players in the respiratory diagnostics market.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Increasing incidence of respiratory disorders
-
Expanding geriatric population and rise in sedentary lifestyles
RESTRAINTS
Impact
Level
Level
-
High cost of diagnostic tests
-
Limited Reimbursements
OPPORTUNITIES
Impact
Level
Level
-
Growing awareness of untreated sleep apnea
-
Increasing demand for POC testing
CHALLENGES
Impact
Level
Level
-
Complexities associated with diagnosis of respiratory infectious diseases
-
Limited access to peripheral lung lesions in bronchoscopy
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Increasing incidence of respiratory disorders
Respiratory ailments like chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and respiratory infections have increasingly become more prevalent through urbanization, pollution, smoking, and the expansive geriatric population worldwide. This prevalence is expected to lead to the demand for advanced diagnostic tools such as spirometry, molecular diagnostics, imaging technologies, and blood gas analyzers for the diagnosis & treatment of respiratory conditions. According to Springer Nature and NCBI, COPD as an illness is the third-leading cause of death in 2023, with 12% of the overall population being recorded to be afflicted with the condition, with 3 million deaths reported in a year. Projections show that 5.4 million deaths will be attributed to COPD by 2060. According to the EU, there is a cost implication of USD 40.14 billion in terms of economic burden subtended by the disease annually. Therefore, the rising incidence of such diseases and the growing need for preventive care are key factors contributing to market growth during the forecast period.
Restraint: High cost of diagnostic tests
Serious discrepancies in the costs of respiratory diagnostic tests, especially in low- and middle-income countries, are expected to limit test uptake during the forecast period. The high cost of diagnostic technologies such as molecular assay tests for conditions such as multidrug-resistant tuberculosis (MDR-TB) further makes patients spend 'mostly out-of-pocket' because of poor insurance or limited public health help. Delayed diagnosis owing to high costs increases the burden of diseases and drives the demand on healthcare facilities for diagnostic services. Therefore, the nonavailability of cost-effective solutions is expected to impact the market's growth significantly during the forecast period.
Opportunity: Growing awareness of untreated sleep apnea
The increasing understanding of the consequences of untreated sleep apnea offers immense potential for respiratory diagnostics. According to ResMed, in the US, the cost of untreated OSA ranges from USD 43 billion to USD 46 billion, whereas undiagnosed cases generate an additional USD 3.4 billion in medical expenses. Similarly, OSA increases the risk for several health outcomes: 140% increased risk for heart failure, 60% increased risk for stroke, and 30% increased risk for coronary heart disease. It is also linked to type 2 diabetes, cognitive deficits, and other health problems. Such considerations have triggered healthcare stakeholders, including government institutions, physicians, and primary stakeholders in the market, to implement programs designed to create awareness concerning the early diagnosis & management of sleep apnea. The trend thus fuels the demand for diagnostic solutions to counter the effects of undiagnosed OSA.
Challenge:Complexities associated with diagnosis of respiratory infectious diseases
Overlapping clinical symptoms with bacterial infection and other conditions like asthma or COPD complicate the diagnosis of viral respiratory infections since these viruses are continuously changing, with most current viral examples being variants of influenza, RSV, and SARS-CoV-2 that could evade existing diagnostic tools. According to the CDC report on RSV in 2022, RSV alone causes 58,000-80,000 hospitalizations annually in the US for children under five; most children, 60-70%, have had an RSV infection by age one. Antigen detector assays, serological tests, and nucleic acid amplification tests (NAATs) are diagnostic technologies developed in recent years. However, each has limitations: rapid immunoassays are limited to specific viruses; serological tests are of little clinical use; and the cost of NAATs is high, coupled with the complexity of PCR, where it may not be feasible in resource-poor settings. Although NAATs, particularly PCR tests, are regarded as the "gold standard" for precision and reliability, the high costs and complexities may restrict widespread implementation, especially in resource-limited settings. This convoluted scenario mandates the rising need for adaptable & low-cost solutions to address the effective prevention of diverse and evolving respiratory pathogens.
Respiratory Diagnostics Market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Deployment of AI-enabled respiratory diagnostic platforms (including cloud-connected spirometry and remote monitoring tools) across hospitals in Spain, Germany, and the UK. | Enhances early detection of COPD and asthma, integrates seamlessly with hospital EHRs and supports telemonitoring for chronic respiratory care. |
 |
Implementation of AI-driven algorithms for respiratory rate and airflow analysis through digital ECG data across cardiopulmonary clinics in Poland and the US. | Enables early recognition of respiratory distress via ECG integration and provides automated analysis for clinicians |
 |
Integration of cloud-based AI software for respiratory pattern assessment through Holter ECG systems across European research centers. | Improves detection of sleep apnea and breathing irregularities and supports remote diagnostics and continuous monitoring. |
 |
Implementation of advanced respiratory monitoring algorithms integrated with patient monitoring systems in hospitals across Japan and the US. | Provides continuous and accurate respiratory rate detection and improves clinical decision-making and patient safety. |
 |
Deployment of integrated cardiorespiratory diagnostic systems (pulmonary function tests, CPET, indirect calorimetry, software workflows) across hospitals, clinics, and research centers globally. | Enables high-precision respiratory and metabolic assessments, streamlines workflow via Ascent software, and offers continuity from diagnostics to monitoring |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The ecosystem analysis of the respiratory diagnostics market comprises the elements present in this market and defines these elements with a demonstration of the bodies involved. It includes products and services, test types, disease indications, type of diagnosis, and end users. Manufacturers include organizations engaged in research, design, product development, optimization, and launch. Distributors include third parties and eCommerce sites linked to the organization for marketing products. Research and product developers include in-house research facilities, contract research organizations, and contract development manufacturing organizations, which play an essential role in outsourcing research for product development to manufacturers. End users are the areas where these devices are used. These end customers include key stakeholders in the supply chain of the respiratory diagnostics devices market and, by extension, the overall medical devices market. However, investors/funders and health regulatory bodies are the primary influencers in this market.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Respiratory Diagnostics Market, By Product & Services
By products & services, the instruments & devices sgement held the largest share in the market. Portable diagnostic devices, including hand-held spirometers, peak flow meters, and mobile imaging devices, can allow for immediate evaluation of lung function and conditions. Early appropriate treatment initiation improves patient outcomes due to possible point-of-care respiratory diagnosis improving diagnostic efficacy. Hence, this justifies a transition to a more personalized, timely care, of which respiratory diagnostic instruments are one element of the changing demands of health care. Innovations in the diagnostic device further fuel the trend by allowing for the most accurate, quickest, and least invasive diagnosis of pulmonary diseases.
Respiratory Diagnostics Market, By Test Type
The molecular diagnostic segment, by test type holds the largest share in the respiratory diagnostic market. This trend is attributed to the growing demand for accurate and rapid diagnostics, particularly in the detection of respiratory infections such as COVID-19 and influenza as well as other viral diseases. Techniques such as PCR and next-generation sequencing are known to be included in molecular diagnostics with their high precision and enabling rapid and reliable results. Such growth in these diagnostic practices is brought about by an increase in infectious diseases and technological advances and by increasing awareness of healthcare. Personalized treatment can thus also be facilitated with molecular diagnostics, which add to its demand in clinical scenarios.
Respiratory Diagnostics Market, By Disease Indication
Asthama segment held the largest share in the market. Personalized asthma management increasingly relies on complex and advanced tools of diagnosis, with regard to the individually focused patients. Such advanced diagnostics for asthma like molecular testing and biomarker analyses help providers to explore the various genetics and molecular bases behind a patient's asthma. By understanding these convolutions, it becomes much easier to establish the most personalized and targeted strategies-they almost begin to be called "target medicine." Hence, the segment specific to asthma in respiratory diagnostics is poised for healthy exposure to rapid growth, due to the improving trend toward the adoption of personalized medicine.
Respiratory Diagnostics Market, By DiagnosisType
Among the various type of diagnosis, the syndromic diagnosis segment is expected to grow at a very fast rate in the global respiratory diagnostics market, as it is capable of rapidly identifying a broad range of organisms with a single diagnostic test. It allows the clinician to institute the most appropriate management in the least possible time, especially in an urgent care setting. The increase in incidence of respiratory infections, a growing demand for rapid diagnostic solutions, and advancements in multiplex PCR and next-generation sequencing technologies will boost the segment growth. In addition, the emerging trend of point-of-care testing and the greater need for cost-effective, efficient diagnostics in resource-poor environments further augment the segment's rapid growth.
Respiratory Diagnostics Market, By End User
With the increasing trend, hospitals and clinics are accepting respiratory diagnostics as a complete part of the routine care model. Seamless inclusion of respiratory diagnostics in hospitals and clinics affords convenience for patients to access diagnostic services, whether they come from seeking primary care or specialized services for a problem. Early detection of diseases, as well as the patient's health in terms of being proactive, as measured by the repeated measures of respiratory health within a specific time frame, helps to determine timely intervention with an individualized treatment plan. Integrated diagnostic measures become part of the patient's care pathway and support immediate intervention based on diagnosis. With hospitals and clinics becoming main sites for respiratory diagnosis in a typical care routine, the demand for such services is bound to expand and, therefore, is expected to be a driver for growth in the respiratory diagnostics market.
REGION
Asia Pacific to be fastest-growing region in global respiratory diagnostics market during forecast period
By region, the Asia Pacific market is expected to dominate the respiratory diagnostics market during the forecast period. The gradual increase in healthcare spending across emerging economies is expected to drive enhanced healthcare outcomes and the uptake of technologically advanced diagnostics. The rising establishment of several diagnostic laboratories in the region is expected to lower the cost of respiratory diagnostics. The increasing number of medical device manufacturers in the region is also expected to contribute to market growth.
Respiratory Diagnostics Market: COMPANY EVALUATION MATRIX
In the respiratory diagnostics market matrix, Philips (Star) leads with scale, extensive distribution, and a broad solutions portfolio. MGC Diagnostics Corporation (Emerging Leader) is gaining momentum with innovative respiratory diagnostic devices. While Philips dominates through reach, MGC Diagnostics Corporation' innovation positions it for rapid growth toward the leaders’ quadrant.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 6..17 BN |
| Market Forecast in 2030 (Value) | USD 9.02 BN |
| CAGR | 6.5% |
| Years Considered | 2022-2030 |
| Base Year | 2023 |
| Forecast Period | 2024-2030 |
| Units Considered | Value (USD Billion), Volume (Thousand Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Asia Pacific, Europe, Latin America, Middle East & Africa |
WHAT IS IN IT FOR YOU: Respiratory Diagnostics Market REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Product Analysis | In-depth assessment of diagnostics devices by test type | The report included market size, key trends, growth opportunities, and a detailed competitive landscape highlighting leading providers, their product differentiators, and strategic positioning |
| Company Information | Key players: Top 3-5 players market share analysis at APAC and European country level. | Insights on revenue shifts towards emerging device innovations. |
| Geographic Analysis | Detailed analysis on Rest of APAC was provided to one of the top players. | Country level demand mapping for new product launches and localization strategy planning. |
RECENT DEVELOPMENTS
- September 2024 : Becton, Dickinson and Company (US) acquired Edwards Lifesciences Corporation’s Critical Care product group. The product group is now renamed BD Advanced Patient Monitoring, unlocking new value opportunities and enhancing BD's innovative connected care solutions portfolio.
- June 2024 : bioMérieux (France) declared that the BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini has received the US FDA Special 510(k) approval and CLIA-waiver (Clinical Laboratory Improvement Amendments). This unique multiplex PCR test detects five of the most common viral & bacterial causes of respiratory or sore throat infections in about 15 minutes.
- Janary 2024 : Wipro GE Healthcare, a Joint Venture (JV) between GE Precision Healthcare LLC (US) and Wipro Enterprises Limited (India), signed a MoU with the Indian Institute of Science (IISc) (India) to advance healthcare innovation, research, and technology development in India.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
33
2
RESEARCH METHODOLOGY
38
3
EXECUTIVE SUMMARY
52
4
PREMIUM INSIGHTS
56
5
MARKET OVERVIEW
Explore the booming respiratory diagnostics market driven by tech advancements and growing health awareness.
59
5.1
INTRODUCTION
5.2
MARKET DYNAMICS
5.2.1
DRIVERS
5.2.1.1
INCREASING INCIDENCE OF RESPIRATORY DISORDERS
5.2.1.2
EXPANDING GERIATRIC POPULATION AND RISE IN SEDENTARY LIFESTYLES
5.2.1.3
GROWING AWARENESS ABOUT RESPIRATORY HEALTH
5.2.1.4
ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES
5.2.2
RESTRAINTS
5.2.2.1
HIGH COST OF DIAGNOSTIC TESTS
5.2.2.2
LIMITED REIMBURSEMENTS
5.2.2.3
SHORTAGE OF SKILLED PROFESSIONALS
5.2.3
OPPORTUNITIES
5.2.3.1
HIGH GROWTH POTENTIAL OF EMERGING ECONOMIES
5.2.3.2
INCREASING DEMAND FOR POC TESTING
5.2.3.3
GROWING AWARENESS ABOUT UNTREATED OSA
5.2.4
CHALLENGES
5.2.4.1
COMPLEXITIES ASSOCIATED WITH DIAGNOSIS OF VIRAL RESPIRATORY INFECTIONS
5.2.4.2
LIMITED ACCESS TO PERIPHERAL LUNG LESIONS IN BRONCHOSCOPY
5.3
INDUSTRY TRENDS
5.3.1
POINT-OF-CARE TESTING
5.3.2
PERSONALIZED MEDICINE
5.4
TECHNOLOGY ANALYSIS
5.4.1
KEY TECHNOLOGIES
5.4.1.1
HOME-BASED & PERSONAL DHTS
5.4.1.2
PFT TOOLS AND MOLECULAR & IMAGING DIAGNOSTICS
5.4.2
COMPLEMENTARY TECHNOLOGIES
5.4.2.1
AI-ENHANCED IMAGING
5.4.2.2
SEROLOGICAL & TELEHEALTH PLATFORMS
5.4.3
ADJACENT TECHNOLOGIES
5.4.3.1
RAPID RESPIRATORY DIAGNOSTIC TESTS
5.5
PORTER’S FIVE FORCES ANALYSIS
5.5.1
THREAT OF NEW ENTRANTS
5.5.2
THREAT OF SUBSTITUTES
5.5.3
BARGAINING POWER OF SUPPLIERS
5.5.4
BARGAINING POWER OF BUYERS
5.5.5
INTENSITY OF COMPETITIVE RIVALRY
5.6
REGULATORY ANALYSIS
5.6.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.6.2
REGULATORY LANDSCAPE
5.6.2.1
NORTH AMERICA
5.6.2.2
EUROPE
5.6.2.3
ASIA PACIFIC
5.6.2.4
LATIN AMERICA
5.6.2.5
MIDDLE EAST & AFRICA
5.7
PATENT ANALYSIS
5.7.1
KEY PATENTS GRANTED
5.8
TRADE ANALYSIS
5.8.1
IMPORT DATA FOR HS CODE 901819
5.8.2
EXPORT DATA FOR HS CODE 901819
5.9
PRICING ANALYSIS
5.9.1
AVERAGE SELLING PRICE OF RESPIRATORY DIAGNOSTIC PRODUCTS, BY KEY PLAYER (2024)
5.9.2
AVERAGE SELLING PRICE TREND OF RESPIRATORY DIAGNOSTIC PRODUCTS, BY REGION, 2021–2023
5.10
VALUE CHAIN ANALYSIS
5.11
KEY STAKEHOLDERS & BUYING CRITERIA
5.11.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.11.2
KEY BUYING CRITERIA
5.12
KEY CONFERENCES & EVENTS, 2024–2025
5.13
UNMET NEEDS/END-USER EXPECTATIONS
5.14
ADJACENT MARKET ANALYSIS
5.15
ECOSYSTEM ANALYSIS
5.16
CASE STUDY ANALYSIS
5.17
SUPPLY CHAIN ANALYSIS
5.18
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.19
INVESTMENT & FUNDING SCENARIO
5.20
REIMBURSEMENT SCENARIO
5.21
IMPACT OF AI/GENERATIVE AI ON RESPIRATORY DIAGNOSTICS MARKET
6
RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 4 Data Tables
100
6.1
INTRODUCTION
6.2
INSTRUMENTS & DEVICES
6.2.1
INTRODUCTION OF AUTOMATED & HIGH-THROUGHPUT INSTRUMENTS TO DRIVE MARKET
6.3
ASSAYS & REAGENTS
6.3.1
INCREASING DEMAND FOR RESPIRATORY DIAGNOSTIC TEST KITS TO PROPEL MARKET
6.4
SERVICES & SOFTWARE
6.4.1
INCREASING DEMAND FOR CONSISTENT UPGRADES AND SUPPORT SERVICES TO FUEL MARKET
7
RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million and Units | 33 Data Tables
106
7.1
INTRODUCTION
7.2
MECHANICAL TESTS
7.2.1
PULMONARY FUNCTION TESTS
7.2.1.1
SPIROMETRY
7.2.1.2
PEAK FLOW TESTS
7.2.1.3
OTHER PULMONARY FUNCTION TESTS
7.2.2
OBSTRUCTIVE SLEEP APNEA DIAGNOSTIC TESTS
7.2.2.1
LARGE PRESENCE OF UNTREATED POPULATION TO DRIVE MARKET
7.2.3
OTHER MECHANICAL TESTS
7.3
IMAGING TESTS
7.3.1
X-RAY
7.3.1.1
INTEGRATION OF AI INTO X-RAY DEVICES FOR ENHANCED IMAGING CAPABILITIES TO DRIVE MARKET
7.3.2
COMPUTED TOMOGRAPHY
7.3.2.1
RISING FOCUS ON OBTAINING HIGH-RESOLUTION CT IMAGES TO BOOST DEMAND
7.3.3
MAGNETIC RESONANCE IMAGING (MRI)
7.3.3.1
ABILITY TO PROVIDE DETAILED LUNG IMAGES WITHOUT RADIATION EXPOSURE TO DRIVE MARKET
7.3.4
POSITRON EMISSION TOMOGRAPHY (PET)
7.3.4.1
GROWING FOCUS ON DETECTION & MONITORING OF TREATMENT RESPONSE TO LUNG CANCER TO DRIVE MARKET
7.3.5
OTHER IMAGING TESTS
7.4
TRADITIONAL DIAGNOSTIC TESTS
7.4.1
IMMUNODIAGNOSTICS
7.4.1.1
RISING DEMAND FOR RAPID DISEASE DIAGNOSIS TO FUEL UPTAKE
7.4.2
BIOCHEMICAL TESTS
7.4.2.1
ABILITY TO ACCURATELY MEASURE BIOMARKERS IN PNEUMONIA AND BRONCHITIS INFECTIONS TO BOOST DEMAND
7.4.3
MICROSCOPY
7.4.3.1
INADEQUATE SENSITIVITY TOWARDS EMERGING VIRUSES TO RESTRAIN MARKET
7.5
MOLECULAR DIAGNOSTIC TESTS
7.5.1
POLYMERASE CHAIN REACTION (PCR)
7.5.1.1
DEVELOPMENT OF PORTABLE AND REAL-TIME PCR MACHINES TO DRIVE MARKET
7.5.2
NUCLEIC ACID AMPLIFICATION TEST (NAAT)
7.5.2.1
RAPID IDENTIFICATION OF VIRAL, BACTERIAL, AND FUNGAL INFECTIONS TO FUEL DEMAND
7.5.3
IN SITU HYBRIDIZATION (ISH)
7.5.3.1
UTILIZATION OF PROBES FOR PATHOGEN DETECTION TO SUPPORT MARKET GROWTH
7.5.4
DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS)
7.5.4.1
HIGH-THROUGHPUT CAPABILITIES FOR RAPID ANALYSIS OF GENETIC DATA TO PROPEL MARKET
7.5.5
MICROARRAYS
7.5.5.1
DETECTION OF HEPATITIS C AND RESPIRATORY VIRUSES TO SUPPORT MARKET GROWTH
7.5.6
OTHER MOLECULAR DIAGNOSTIC TESTS
8
RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 11 Data Tables
141
8.1
INTRODUCTION
8.2
TUBERCULOSIS
8.2.1
FAVORABLE FUNDING INITIATIVES FOR TB TREATMENT TO DRIVE MARKET
8.3
ASTHMA
8.3.1
INCREASING AIR POLLUTION AND GROWING USE OF TOBACCO-BASED PRODUCTS TO DRIVE MARKET
8.4
LUNG CANCER
8.4.1
NON-SMALL-CELL LUNG CANCER (NSCLC)
8.4.1.1
RISING INVESTMENTS IN ADVANCED RADIOGRAPHIC TECHNOLOGIES TO FUEL MARKET
8.4.2
SMALL-CELL LUNG CANCER (SCLC)
8.4.2.1
GROWING EMPHASIS ON PRECISION TESTING TO DRIVE MARKET
8.4.3
OTHER LUNG CANCERS
8.5
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
8.5.1
ADVANCEMENTS IN SPIROMETRY AND PLETHYSMOGRAPHY FOR COPD DIAGNOSIS TO FUEL MARKET
8.6
PNEUMONIA
8.6.1
RISING INCIDENCE OF RESPIRATORY INFECTIONS TO BOOST DEMAND
8.7
OTHER DISEASES
9
RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 4 Data Tables
154
9.1
INTRODUCTION
9.2
SYNDROMIC DIAGNOSIS
9.2.1
DETECTION OF MULTIPLE PANELS OF VIRAL PATHOGENS TO PROPEL MARKET
9.3
ETIOLOGICAL DIAGNOSIS
9.3.1
IDENTIFICATION OF SPECIFIC CAUSE OF RESPIRATORY ILLNESSES TO FUEL MARKET
9.4
PROGNOSIS DIAGNOSIS
9.4.1
ASSESSMENT OF BIOMARKERS FOR DISEASE PROGRESSION TO SUPPORT MARKET GROWTH
10
RESPIRATORY DIAGNOSTICS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 5 Data Tables
160
10.1
INTRODUCTION
10.2
HOSPITALS & CLINICS
10.2.1
GROWING ACCESSIBILITY TO ADVANCED EQUIPMENT TO FUEL MARKET
10.3
DIAGNOSTIC LABORATORIES
10.3.1
ABILITY TO PROVIDE AFFORDABLE TESTING PROCESSES WITH TIMELY RESULTS TO BOOST DEMAND
10.4
LONG-TERM CARE & SPECIALTY CENTERS
10.4.1
PROVISION OF SPECIALIZED & ADVANCED SERVICES TO PROPEL MARKET
10.5
ACADEMIC & RESEARCH INSTITUTES
10.5.1
FAVORABLE FUNDING INITIATIVES TO SUPPORT MARKET GROWTH
11
RESPIRATORY DIAGNOSTICS MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 18 Countries | 320 Data Tables.
166
11.1
INTRODUCTION
11.2
NORTH AMERICA
11.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2
US
11.2.2.1
GROWING ACCESSIBILITY TO TECHNOLOGICALLY ADVANCED PRODUCTS TO BOOST DEMAND
11.2.3
CANADA
11.2.3.1
RISING INCIDENCE OF COPD TO DRIVE MARKET
11.3
EUROPE
11.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2
GERMANY
11.3.2.1
INCREASING PUBLIC HEALTHCARE EXPENDITURE TO FOSTER MARKET GROWTH
11.3.3
UK
11.3.3.1
RISING ESTABLISHMENT OF HOSPITALS AND INCREASING NUMBER OF SURGICAL PROCEDURES TO FUEL MARKET
11.3.4
FRANCE
11.3.4.1
HIGH PREVALENCE OF SMOKING AND INCREASING DEMAND FOR RESPIRATORY DEVICES TO DRIVE MARKET
11.3.5
ITALY
11.3.5.1
UNFAVORABLE AMENDMENTS TO HEALTHCARE POLICIES TO RESTRAIN MARKET
11.3.6
SPAIN
11.3.6.1
INCREASING DEMAND FOR HOME HEALTHCARE SERVICES TO SUPPORT MARKET GROWTH
11.3.7
REST OF EUROPE
11.4
ASIA PACIFIC
11.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2
JAPAN
11.4.2.1
AVAILABILITY OF UNIVERSAL HEALTHCARE REIMBURSEMENT POLICY TO DRIVE MARKET
11.4.3
CHINA
11.4.3.1
HIGH INCIDENCE OF VIRAL RESPIRATORY INFECTIONS TO PROPEL MARKET
11.4.4
INDIA
11.4.4.1
EXPANSION OF LEADING MEDICAL DEVICE MANUFACTURERS AND LARGE TARGET PATIENT POPULATION TO DRIVE MARKET
11.4.5
AUSTRALIA
11.4.5.1
HIGH PREVALENCE OF CHRONIC LUNG DISEASES TO BOOST DEMAND
11.4.6
SOUTH KOREA
11.4.6.1
EXPANDING GERIATRIC POPULATION AND RISING INCIDENCE OF CHRONIC RESPIRATORY CONDITIONS TO FUEL MARKET
11.4.7
REST OF ASIA PACIFIC
11.5
LATIN AMERICA
11.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2
BRAZIL
11.5.2.1
FAVORABLE GOVERNMENT INITIATIVES FOR HEALTHCARE SECTOR IMPROVEMENT TO DRIVE MARKET
11.5.3
MEXICO
11.5.3.1
RISING PREVALENCE OF OBESITY & HYPERTENSION TO FUEL UPTAKE
11.5.4
REST OF LATIN AMERICA
11.6
MIDDLE EAST & AFRICA
11.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
11.6.2
GCC COUNTRIES
11.6.2.1
KINGDOM OF SAUDI ARABIA (KSA)
11.6.2.2
UNITED ARAB EMIRATES (UAE)
11.6.2.3
OTHER GCC COUNTRIES
11.6.3
REST OF MIDDLE EAST & AFRICA
12
COMPETITIVE LANDSCAPE
Discover top strategies and emerging leaders shaping market dynamics and growth opportunities.
290
12.1
INTRODUCTION
12.2
KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2021–DECEMBER 2024
12.3
REVENUE ANALYSIS, 2019–2023
12.4
MARKET SHARE ANALYSIS, 2023
12.4.1
RANKING OF KEY MARKET PLAYERS
12.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1
STARS
12.5.2
EMERGING LEADERS
12.5.3
PERVASIVE PLAYERS
12.5.4
PARTICIPANTS
12.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5.1
COMPANY FOOTPRINT
12.5.5.2
REGION FOOTPRINT
12.5.5.3
PRODUCT & SERVICE FOOTPRINT
12.5.5.4
TEST TYPE FOOTPRINT
12.5.5.5
DISEASE TYPE FOOTPRINT
12.5.5.6
END-USER FOOTPRINT
12.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.6.1
PROGRESSIVE COMPANIES
12.6.2
RESPONSIVE COMPANIES
12.6.3
DYNAMIC COMPANIES
12.6.4
STARTING BLOCKS
12.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.7
BRAND/PRODUCT COMPARISON
12.8
R&D EXPENDITURE OF KEY PLAYERS
12.9
COMPANY VALUATION & FINANCIAL METRICS
12.9.1
FINANCIAL METRICS
12.9.2
COMPANY VALUATION
12.10
COMPETITIVE SCENARIO
12.10.1
PRODUCT & SERVICE LAUNCHES AND APPROVALS
12.10.2
DEALS
12.10.3
EXPANSIONS
12.10.4
OTHER DEVELOPMENTS
13
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
313
13.1
KEY PLAYERS
13.1.1
KONINKLIJKE PHILIPS N.V.
13.1.1.1
BUSINESS OVERVIEW
13.1.1.2
PRODUCTS & SERVICES OFFERED
13.1.1.3
RECENT DEVELOPMENTS
13.1.1.4
MNM VIEW
13.1.2
BECTON, DICKINSON AND COMPANY
13.1.3
ABBOTT LABORATORIES
13.1.4
THERMO FISHER SCIENTIFIC INC.
13.1.5
GE HEALTHCARE TECHNOLOGIES, INC.
13.1.6
BIO-RAD LABORATORIES, INC.
13.1.7
BIOMÉRIEUX
13.1.8
REVVITY, INC.
13.1.9
SEEGENE INC.
13.1.10
NIHON KOHDEN CORPORATION
13.1.11
VITALOGRAPH
13.1.12
SDI DIAGNOSTICS
13.1.13
RESMED INC.
13.1.14
SIEMENS HEALTHINEERS AG
13.1.15
COSMED SRL
13.1.16
HOLOGIC, INC.
13.1.17
QIAGEN N.V.
13.2
OTHER PLAYERS
13.2.1
MGC DIAGNOSTICS CORPORATION
13.2.2
VISBY MEDICAL, INC.
13.2.3
BRIOTA TECHNOLOGIES PVT. LTD.
13.2.4
BIRD HEALTHCARE
13.2.5
LÖWENSTEIN MEDICAL SE & CO. KG
13.2.6
PROAXSIS
13.2.7
NDD MEDICAL TECHNOLOGIES
13.2.8
COMPUMEDICS LIMITED
14
APPENDIX
391
14.1
DISCUSSION GUIDE
14.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3
CUSTOMIZATION OPTIONS
14.4
RELATED REPORTS
14.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
RESPIRATORY DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2
EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
TABLE 3
RESPIRATORY DIAGNOSTICS MARKET: STUDY ASSUMPTIONS
TABLE 4
RESPIRATORY DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
TABLE 5
AWARENESS INITIATIVES ON EFFECTS OF UNTREATED SLEEP APNEA
TABLE 6
RESPIRATORY DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 7
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12
US: CLASSIFICATION OF MEDICAL EQUIPMENT
TABLE 13
US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 14
CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 15
EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 16
CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 17
JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 18
RESPIRATORY DIAGNOSTICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022−2024
TABLE 19
IMPORT DATA FOR HS CODE 901819, BY COUNTRY, 2019–2023 (USD THOUSAND)
TABLE 20
EXPORT DATA FOR HS CODE 901819, BY COUNTRY, 2019–2023 (USD THOUSAND)
TABLE 21
AVERAGE SELLING PRICE TREND OF RESPIRATORY DIAGNOSTIC PRODUCTS, BY REGION, 2021–2023 (USD)
TABLE 22
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY DIAGNOSTIC DEVICES
TABLE 23
KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES
TABLE 24
RESPIRATORY DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2024−2025
TABLE 25
RESPIRATORY DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
TABLE 26
CASE STUDY 1: ACUPEBBLE SA100 – TRANSFORMING SLEEP APNEA DIAGNOSIS
TABLE 27
CASE STUDY 2: REMOTE MONITORING SOLUTION FOR COVID-19 PATIENTS IN INDONESIA
TABLE 28
CASE STUDY 3: EFFECTIVE MANAGEMENT OF A 71-YEAR-OLD COPD PATIENT WITH ACUTE EXACERBATIONS
TABLE 29
RESPIRATORY DIAGNOSTICS MARKET: REIMBURSEMENT SCENARIO
TABLE 30
RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 31
RESPIRATORY DIAGNOSTICS MARKET FOR INSTRUMENTS & DEVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 32
RESPIRATORY DIAGNOSTICS MARKET FOR ASSAYS & REAGENTS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 33
RESPIRATORY DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 34
RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 35
RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 36
RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2022–2030 (USD MILLION)
TABLE 37
RESPIRATORY DIAGNOSTICS MARKET FOR PULMONARY FUNCTION TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 38
RESPIRATORY DIAGNOSTICS MARKET FOR PULMONARY FUNCTION TESTS, BY TYPE, 2022–2030 (USD MILLION)
TABLE 39
SPIROMETRY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 40
SPIROMETRY TESTS MARKET, BY REGION, 2022–2030 (THOUSAND UNITS)
TABLE 41
PEAK FLOW TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 42
PEAK FLOW TESTS MARKET, BY REGION, 2022–2030 (THOUSAND UNITS)
TABLE 43
OTHER PULMONARY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 44
OTHER PULMONARY TESTS MARKET, BY REGION, 2022–2030 (THOUSAND UNITS)
TABLE 45
OBSTRUCTIVE SLEEP APNEA DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 46
OTHER MECHANICAL TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 47
RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 48
RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2022–2030 (USD MILLION)
TABLE 49
X-RAY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 50
COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 51
MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 52
POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 53
OTHER IMAGING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 54
RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 55
RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2022–2030 (USD MILLION)
TABLE 56
IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 57
BIOCHEMICAL TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 58
MICROSCOPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 59
RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 60
RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2022–2030 (USD MILLION)
TABLE 61
PCR MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 62
NUCLEIC ACID AMPLIFICATION TEST MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 63
IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 64
DNA SEQUENCING & NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 65
MICROARRAYS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 66
OTHER MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 67
RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 68
RESPIRATORY DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 69
RESPIRATORY DIAGNOSTICS MARKET FOR ASTHMA, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 70
RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 71
RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER, BY TYPE, 2022–2030 (USD MILLION)
TABLE 72
NON-SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 73
SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 74
OTHER LUNG CANCERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 75
RESPIRATORY DIAGNOSTICS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 76
RESPIRATORY DIAGNOSTICS MARKET FOR PNEUMONIA, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 77
RESPIRATORY DIAGNOSTICS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 78
RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 79
SYNDROMIC DIAGNOSIS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 80
ETIOLOGICAL DIAGNOSIS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 81
PROGNOSIS DIAGNOSIS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 82
RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 83
RESPIRATORY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 84
RESPIRATORY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 85
RESPIRATORY DIAGNOSTICS MARKET FOR LONG-TERM CARE & SPECIALTY CENTERS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 86
RESPIRATORY DIAGNOSTICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 87
RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2022–2030 (USD MILLION)
TABLE 88
NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 89
NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 90
NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 91
NORTH AMERICA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 92
NORTH AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 93
NORTH AMERICA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 94
NORTH AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 95
NORTH AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 96
NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 97
NORTH AMERICA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 98
NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 99
NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 100
US: KEY MACROINDICATORS
TABLE 101
US: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 102
US: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 103
US: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 104
US: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 105
US: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 106
US: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 107
US: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 108
US: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 109
US: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 110
US: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 111
US: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 112
CANADA: KEY MACROINDICATORS
TABLE 113
CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 114
CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 115
CANADA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 116
CANADA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 117
CANADA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 118
CANADA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 119
CANADA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 120
CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 121
CANADA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 122
CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 123
CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 124
EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 125
EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 126
EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 127
EUROPE: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 128
EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 129
EUROPE: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 130
EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 131
EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 132
EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 133
EUROPE: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 134
EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 135
EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 136
GERMANY: KEY MACROINDICATORS
TABLE 137
GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 138
GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 139
GERMANY: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 140
GERMANY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 141
GERMANY: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 142
GERMANY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 143
GERMANY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 144
GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 145
GERMANY: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 146
GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 147
GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 148
UK: KEY MACROINDICATORS
TABLE 149
UK: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 150
UK: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 151
UK: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 152
UK: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 153
UK: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 154
UK: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 155
UK: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 156
UK: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 157
UK: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 158
UK: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 159
UK: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 160
FRANCE: KEY MACROINDICATORS
TABLE 161
FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 162
FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 163
FRANCE: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 164
FRANCE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 165
FRANCE: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 166
FRANCE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 167
FRANCE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 168
FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 169
FRANCE: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 170
FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 171
FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 172
ITALY: KEY MACROINDICATORS
TABLE 173
ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 174
ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 175
ITALY: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 176
ITALY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 177
ITALY: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 178
ITALY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 179
ITALY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 180
ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 181
ITALY: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 182
ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 183
ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 184
SPAIN: KEY MACROINDICATORS
TABLE 185
SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 186
SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 187
SPAIN: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 188
SPAIN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 189
SPAIN: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 190
SPAIN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 191
SPAIN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 192
SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 193
SPAIN: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 194
SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 195
SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 196
REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 197
REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 198
REST OF EUROPE: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 199
REST OF EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 200
REST OF EUROPE: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 201
REST OF EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 202
REST OF EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 203
REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 204
REST OF EUROPE: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 205
REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 206
REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 207
ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 208
ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 209
ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 210
ASIA PACIFIC: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 211
ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 212
ASIA PACIFIC: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 213
ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 214
ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 215
ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 216
ASIA PACIFIC: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 217
ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 218
ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 219
JAPAN: KEY MACROINDICATORS
TABLE 220
JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 221
JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 222
JAPAN: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 223
JAPAN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 224
JAPAN: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 225
JAPAN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 226
JAPAN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 227
JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 228
JAPAN: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 229
JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 230
JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 231
CHINA: KEY MACROINDICATORS
TABLE 232
CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 233
CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 234
CHINA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 235
CHINA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 236
CHINA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 237
CHINA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 238
CHINA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 239
CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 240
CHINA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 241
CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 242
CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 243
INDIA: KEY MACROINDICATORS
TABLE 244
INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 245
INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 246
INDIA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 247
INDIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 248
INDIA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 249
INDIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 250
INDIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 251
INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 252
INDIA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 253
INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 254
INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 255
AUSTRALIA: KEY MACROINDICATORS
TABLE 256
AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 257
AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 258
AUSTRALIA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 259
AUSTRALIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 260
AUSTRALIA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 261
AUSTRALIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 262
AUSTRALIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 263
AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 264
AUSTRALIA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 265
AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 266
AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 267
SOUTH KOREA: KEY MACROINDICATORS
TABLE 268
SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 269
SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 270
SOUTH KOREA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 271
SOUTH KOREA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 272
SOUTH KOREA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 273
SOUTH KOREA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 274
SOUTH KOREA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 275
SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 276
SOUTH KOREA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 277
SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 278
SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 279
REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 280
REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 281
REST OF ASIA PACIFIC: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 282
REST OF ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 283
REST OF ASIA PACIFIC: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 284
REST OF ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 285
REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 286
REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 287
REST OF ASIA PACIFIC: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 288
REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 289
REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 290
LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 291
LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 292
LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 293
LATIN AMERICA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 294
LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 295
LATIN AMERICA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 296
LATIN AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 297
LATIN AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 298
LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 299
LATIN AMERICA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 300
LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 301
LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 302
BRAZIL: KEY MACROINDICATORS
TABLE 303
BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 304
BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 305
BRAZIL: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 306
BRAZIL: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 307
BRAZIL: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 308
BRAZIL: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 309
BRAZIL: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 310
BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 311
BRAZIL: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 312
BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 313
BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 314
MEXICO: KEY MACROINDICATORS
TABLE 315
MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 316
MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 317
MEXICO: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 318
MEXICO: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 319
MEXICO: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 320
MEXICO: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 321
MEXICO: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 322
MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 323
MEXICO: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 324
MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 325
MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 326
REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 327
REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 328
REST OF LATIN AMERICA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 329
REST OF LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 330
REST OF LATIN AMERICA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 331
REST OF LATIN AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 332
REST OF LATIN AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 333
REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 334
REST OF LATIN AMERICA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 335
REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 336
REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 337
MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2022–2030 (USD MILLION)
TABLE 338
MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 339
MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 340
MIDDLE EAST & AFRICA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 341
MIDDLE EAST & AFRICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 342
MIDDLE EAST & AFRICA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 343
MIDDLE EAST & AFRICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 344
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 345
MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 346
MIDDLE EAST & AFRICA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 347
MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 348
MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 349
GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 350
GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 351
GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 352
GCC COUNTRIES: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 353
GCC COUNTRIES: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 354
GCC COUNTRIES: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 355
GCC COUNTRIES: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 356
GCC COUNTRIES: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 357
GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 358
GCC COUNTRIES: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 359
GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 360
GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 361
KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS
TABLE 362
KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 363
KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 364
KINGDOM OF SAUDI ARABIA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 365
KINGDOM OF SAUDI ARABIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 366
KINGDOM OF SAUDI ARABIA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 367
KINGDOM OF SAUDI ARABIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 368
KINGDOM OF SAUDI ARABIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 369
KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 370
KINGDOM OF SAUDI ARABIA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 371
KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 372
KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 373
UNITED ARAB EMIRATES: KEY MACROINDICATORS
TABLE 374
UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 375
UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 376
UNITED ARAB EMIRATES: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 377
UNITED ARAB EMIRATES: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 378
UNITED ARAB EMIRATES: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 379
UNITED ARAB EMIRATES: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 380
UNITED ARAB EMIRATES: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 381
UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 382
UNITED ARAB EMIRATES: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 383
UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 384
UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 385
OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 386
OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 387
OTHER GCC COUNTRIES: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 388
OTHER GCC COUNTRIES: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 389
OTHER GCC COUNTRIES: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 390
OTHER GCC COUNTRIES: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 391
OTHER GCC COUNTRIES: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 392
OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 393
OTHER GCC COUNTRIES: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 394
OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 395
OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 396
REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
TABLE 397
REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 398
REST OF MIDDLE EAST & AFRICA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 399
REST OF MIDDLE EAST & AFRICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 400
REST OF MIDDLE EAST & AFRICA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 401
REST OF MIDDLE EAST & AFRICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 402
REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 403
REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
TABLE 404
REST OF MIDDLE EAST & AFRICA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 405
REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
TABLE 406
REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 407
RESPIRATORY DIAGNOSTIC MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2021–DECEMBER 2024
TABLE 408
RESPIRATORY DIAGNOSTICS MARKET: DEGREE OF COMPETITION, 2023
TABLE 409
RESPIRATORY DIAGNOSTICS MARKET: REGIONAL FOOTPRINT
TABLE 410
RESPIRATORY DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
TABLE 411
RESPIRATORY DIAGNOSTICS MARKET: TEST TYPE FOOTPRINT
TABLE 412
RESPIRATORY DIAGNOSTICS MARKET: DISEASE TYPE FOOTPRINT
TABLE 413
RESPIRATORY DIAGNOSTICS MARKET: END-USER FOOTPRINT
TABLE 414
RESPIRATORY DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
TABLE 415
RESPIRATORY DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
TABLE 416
RESPIRATORY DIAGNOSTICS MARKET: PRODUCT & SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
TABLE 417
RESPIRATORY DIAGNOSTICS MARKET: DEALS, JANUARY 2021–DECEMBER 2024
TABLE 418
RESPIRATORY DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021–DECEMBER 2024
TABLE 419
RESPIRATORY DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–DECEMBER 2024
TABLE 420
KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
TABLE 421
KONINKLIJKE PHILIPS N.V.: PRODUCTS & SERVICES OFFERED
TABLE 422
KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024
TABLE 423
KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021–DECEMBER 2024
TABLE 424
KONINKLIJKE PHILIPS N.V.: EXPANSIONS, JANUARY 2021–DECEMBER 2024
TABLE 425
BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
TABLE 426
BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED
TABLE 427
BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
TABLE 428
BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2021–DECEMBER 2024
TABLE 429
ABBOTT LABORATORIES: COMPANY OVERVIEW
TABLE 430
ABBOTT LABORATORIES: PRODUCTS & SERVICES OFFERED
TABLE 431
ABBOTT LABORATORIES: PRODUCT APPROVALS, JANUARY 2021–DECEMBER 2024
TABLE 432
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 433
THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
TABLE 434
THERMO FISHER SCIENTIFIC INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2021–DECEMBER 2024
TABLE 435
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–DECEMBER 2024
TABLE 436
GE HEALTHCARE TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 437
GE HEALTHCARE TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
TABLE 438
GE HEALTHCARE TECHNOLOGIES, INC.: PRODUCT & SERVICE LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
TABLE 439
GE HEALTHCARE TECHNOLOGIES, INC.: DEALS, JANUARY 2021–DECEMBER 2024
TABLE 440
GE HEALTHCARE TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2024
TABLE 441
BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 442
BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
TABLE 443
BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
TABLE 444
BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021–DECEMBER 2024
TABLE 445
BIOMÉRIEUX: COMPANY OVERVIEW
TABLE 446
BIOMÉRIEUX: PRODUCTS & SERVICES OFFERED
TABLE 447
BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
TABLE 448
BIOMÉRIEUX: DEALS, JANUARY 2021–DECEMBER 2024
TABLE 449
REVVITY, INC.: COMPANY OVERVIEW
TABLE 450
REVVITY, INC.: PRODUCTS & SERVICES OFFERED
TABLE 451
REVVITY, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
TABLE 452
REVVITY, INC.: DEALS, JANUARY 2021–DECEMBER 2024
TABLE 453
SEEGENE INC.: COMPANY OVERVIEW
TABLE 454
SEEGENE INC.: PRODUCTS & SERVICES OFFERED
TABLE 455
SEEGENE INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
TABLE 456
SEEGENE INC.: DEALS, JANUARY 2021–DECEMBER 2024
TABLE 457
SEEGENE INC.: EXPANSIONS, JANUARY 2021–DECEMBER 2024
TABLE 458
SEEGENE INC.: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2024
TABLE 459
NIHON KOHDEN CORPORATION: COMPANY OVERVIEW
TABLE 460
NIHON KOHDEN CORPORATION: PRODUCTS & SERVICES OFFERED
TABLE 461
VITALOGRAPH: COMPANY OVERVIEW
TABLE 462
VITALOGRAPH: PRODUCTS & SERVICES OFFERED
TABLE 463
VITALOGRAPH: PRODUCT & SERVICE LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
TABLE 464
VITALOGRAPH: DEALS, JANUARY 2021–DECEMBER 2024
TABLE 465
SDI DIAGNOSTICS: COMPANY OVERVIEW
TABLE 466
SDI DIAGNOSTICS: PRODUCTS & SERVICES OFFERED
TABLE 467
RESMED INC.: COMPANY OVERVIEW
TABLE 468
RESMED INC.: PRODUCTS & SERVICES OFFERED
TABLE 469
RESMED INC.: DEALS, JANUARY 2021–DECEMBER 2024
TABLE 470
RESMED INC.: EXPANSIONS, JANUARY 2021–DECEMBER 2024
TABLE 471
RESMED INC.: OTHER DEVELOPMENTS, JANUARY 2021–DECEMBER 2024
TABLE 472
SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
TABLE 473
SIEMENS HEALTHINEERS AG: PRODUCTS & SERVICES OFFERED
TABLE 474
SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024
TABLE 475
SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021–DECEMBER 2024
TABLE 476
SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021–DECEMBER 2024
TABLE 477
COSMED SRL: COMPANY OVERVIEW
TABLE 478
COSMED SRL: PRODUCTS & SERVICES OFFERED
TABLE 479
COSMED SRL: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024
TABLE 480
COSMED SRL: DEALS, JANUARY 2021–DECEMBER 2024
TABLE 481
HOLOGIC, INC.: COMPANY OVERVIEW
TABLE 482
HOLOGIC, INC.: PRODUCTS & SERVICES OFFERED
TABLE 483
HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024
TABLE 484
HOLOGIC, INC.: DEALS, JANUARY 2021–DECEMBER 2024
TABLE 485
QIAGEN N.V.: COMPANY OVERVIEW
TABLE 486
QIAGEN N.V.: PRODUCTS & SERVICES OFFERED
TABLE 487
QIAGEN N.V.: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024
TABLE 488
QIAGEN N.V.: DEALS, JANUARY 2021–DECEMBER 2024
TABLE 489
QIAGEN N.V.: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2024
LIST OF FIGURES
FIGURE 1
RESPIRATORY DIAGNOSTICS MARKET: MARKET & REGIONAL SPREAD
FIGURE 2
RESPIRATORY DIAGNOSTICS MARKET: YEARS CONSIDERED
FIGURE 3
RESEARCH DESIGN
FIGURE 4
RESPIRATORY DIAGNOSTICS MARKET: KEY PRIMARY SOURCES
FIGURE 5
RESPIRATORY DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
FIGURE 6
RESPIRATORY DIAGNOSTICS MARKET: KEY INDUSTRY INSIGHTS
FIGURE 7
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 8
BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 9
BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
FIGURE 10
SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 11
REVENUE SHARE ANALYSIS ILLUSTRATION: KONINKLIJKE PHILIPS N.V. (2023)
FIGURE 12
SUPPLY-SIDE ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET (2023)
FIGURE 13
RESPIRATORY DIAGNOSTICS MARKET: TOP-DOWN APPROACH
FIGURE 14
CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 15
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 16
RESPIRATORY DIAGNOSTICS MARKET: DATA TRIANGULATION METHODOLOGY
FIGURE 17
RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2030 (USD MILLION)
FIGURE 18
RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2024 VS. 2030 (USD MILLION)
FIGURE 19
RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2024 VS. 2030 (USD MILLION)
FIGURE 20
RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2024 VS. 2030 (USD MILLION)
FIGURE 21
RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)
FIGURE 22
GEOGRAPHIC SNAPSHOT OF RESPIRATORY DIAGNOSTICS MARKET
FIGURE 23
RISING PREVALENCE OF RESPIRATORY DISEASES TO PROPEL MARKET
FIGURE 24
INSTRUMENTS & DEVICES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN CHINA (2023)
FIGURE 25
ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 26
INDIA TO GROW AT HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 27
RESPIRATORY DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 28
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) DALY FOR INDIVIDUALS IN AUSTRALIA, BY AGE (2023)
FIGURE 29
GLOBAL GERIATRIC POPULATION, BY REGION
FIGURE 30
RESPIRATORY DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 31
NUMBER OF PATENTS PUBLISHED, JANUARY 2014–DECEMBER 2024
FIGURE 32
TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR RESPIRATORY DIAGNOSTICS DEVICES (JANUARY 2014– DECEMBER 2024)
FIGURE 33
TOP PATENT APPLICANTS, BY JURISDICTION, JANUARY 2014−DECEMBER 2024
FIGURE 34
AVERAGE SELLING PRICE OF SPIROMETERS, BY KEY PLAYER (2024)
FIGURE 35
AVERAGE SELLING PRICE OF PEAK FLOWMETERS, BY KEY PLAYER (2024)
FIGURE 36
RESPIRATORY DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
FIGURE 37
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY DIAGNOSTIC DEVICES
FIGURE 38
KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES
FIGURE 39
RESPIRATORY DIAGNOSTICS MARKET: ADJACENT MARKETS
FIGURE 40
RESPIRATORY DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
FIGURE 41
RESPIRATORY DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 42
RESPIRATORY DIAGNOSTICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 43
RESPIRATORY DIAGNOSTICS MARKET: NUMBER OF DEALS, 2020–2024
FIGURE 44
RESPIRATORY DIAGNOSTICS MARKET: IMPACT OF AI/GEN AI
FIGURE 45
RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
FIGURE 46
NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
FIGURE 47
ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
FIGURE 48
RESPIRATORY DIAGNOSTICS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2019−2023
FIGURE 49
MARKET SHARE ANALYSIS OF KEY PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET (2023)
FIGURE 50
RANKING OF KEY PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET, 2023
FIGURE 51
RESPIRATORY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 52
RESPIRATORY DIAGNOSTICS MARKET: COMPANY FOOTPRINT
FIGURE 53
RESPIRATORY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 54
RESPIRATORY DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 55
R&D EXPENDITURE OF KEY PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET, 2022−2024
FIGURE 56
EV/EBITDA OF KEY VENDORS
FIGURE 57
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 58
KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)
FIGURE 59
BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024)
FIGURE 60
ABBOTT LABORATORIES: COMPANY SNAPSHOT (2023)
FIGURE 61
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
FIGURE 62
GE HEALTHCARE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
FIGURE 63
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
FIGURE 64
BIOMÉRIEUX: COMPANY SNAPSHOT (2023)
FIGURE 65
REVVITY, INC.: COMPANY SNAPSHOT (2023)
FIGURE 66
SEEGENE INC.: COMPANY SNAPSHOT (2023)
FIGURE 67
NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2023)
FIGURE 68
RESMED INC.: COMPANY SNAPSHOT (2024)
FIGURE 69
SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
FIGURE 70
HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
FIGURE 71
QIAGEN N.V.: COMPANY SNAPSHOT (2023)
Methodology
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
This research study involved the usage of comprehensive secondary sources; directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the respiratory diagnostics market. It was also used to obtain important information about the key players, market classification and segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, chief medical information officers related to the respiratory diagnostics markets. Primary sources from the demand side include professionals from hospitals and clinics, diagnostics laboratories, professors, and researcher.
A breakdown of the primary respondents is provided below:
Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
Note 2: Other primaries include sales managers, marketing managers, and product managers.
Note 3: Tiers are defined based on a company’s total revenue. As of 2023: Tier 1 = >USD 500 million, Tier 2 = USD 200 million to USD 500 million, and Tier 3 = < USD 200 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the respiratory diagnostics market was arrived at after data triangulation from three different approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. The following figure shows the market validation, source structure, and data triangulation methodology implemented in the market engineering process.
Market Definition
Respiratory diagnostic devices assess and monitor the functioning of the respiratory system and play a crucial role in diagnosing and managing various respiratory conditions. They include a wide range of equipment that aids in breathing, improves pulmonary function, and assists in the removal of mucus from the airways. Some of the respiratory diagnostic tests include mechanical tests such as Spirometry, Pulse Oximetry, Bronchoscopy, Diagnostic Imaging tests, and in vitro diagnostic tests.
Stakeholders
- Respiratory diagnostic device manufacturers and distributors
- Healthcare institutions (hospitals, laboratories, medical schools, and outpatient clinics)
- Research institutes
- Contract manufacturing organizations (CMOs)
- Government associations
- Market research and consulting firms
- Venture capitalists and investors
- Market research and consulting firms
Report Objectives
- To define, describe, and forecast the respiratory diagnostics market by product and service, test type, disease indication, type of diagnosis, end user, and region
- To provide detailed information about the key factors influencing the market growth, such as drivers, restraints, opportunities, challenges, and industry trends
- To strategically analyze the regulatory scenario, Porter’s Five Forces, value chain, supply chain, ecosystem market/map, recession, and patents in the market
- To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall respiratory diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
- To strategically profile the key players in this market and comprehensively analyze their market shares and core competencies
- To strategically analyze the respiratory diagnostics market in five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To track and analyze competitive developments such as acquisitions, product launches, partnerships, and expansions in the respiratory diagnostics market.
Key Questions Addressed by the Report
What are the emerging trends in the respiratory diagnostics market?
The growing demand for enhanced POC devices, the importance of digitized devices, and reagent rentals are expected to be the key market trends in the respiratory diagnostics market.
Which segments have been included in this report?
This report has the following segments:
- By Product & Service
- By Test Type
- By Disease Type
- By Diagnosis Type
- By End User
- By Region
Which are the top industry players in the respiratory diagnostics market?
The top market players in the global respiratory diagnostics market are Koninklijke Philips N.V. (Netherlands), Becton, Dickinson and Company (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), GE HealthCare Technologies Inc. (US), and Bio-Rad Laboratories, Inc. (US), among others.
What are the factors expected to pose a challenge to the growth of the respiratory diagnostics market?
Complexities associated with the diagnosis of viral respiratory infections and the limited access to peripheral lung lesions in bronchoscopy are factors expected to challenge this market's growth during the forecast period.
By product & service, which segment accounted for the largest share of the respiratory diagnostics market in 2023?
The instruments & services segment accounted for the largest market share in 2023. The large share of this segment can be attributed to the expansion of diagnostic labs in emerging markets; the increasing number of buyers for diagnostics tests; rising technological advancements in instruments; and the trend of reagents on a rental basis.
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Respiratory Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Before You Go
Expand Beyond Respiratory Diagnostics Market
Explore the top 20 industries influencing your market growth
Human and AI Powered Market Intelligence
Find Untapped Markets
Growth opportunities and latent adjacency in Respiratory Diagnostics Market